Concordant KRAS Mutations in Primary and Metastatic Colorectal Cancer Tissue Specimens: A Meta-Analysis and Systematic Review

By Han Cheng-Bo   Li Fan   Ma Jie-Tao   Zou Hua-Wei  

Cancer Investigation, Vol. 30, Iss. 10, 2012-12 ,pp. : 741-747

Informa Healthcare

Access to resources Recommend Favorite

Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS

By Kishiki Tomokazu   Ohnishi Hiroaki   Masaki Tadahiko   Ohtsuka Kouki   Ohkura Yasuo   Furuse Jyunji   Watanabe Takashi   Sugiyama Masanori  

Cancer Chemotherapy and Pharmacology, Vol. 73, Iss. 4, 2014-04 ,pp. : 749-757

Springer Publishing Company

Access to resources Recommend Favorite

Anti-VEGF and Anti-EGFR Monoclonal Antibodies in the First-line Therapy for Metastatic Colorectal Cancer - A Meta-Analysis

By  

Current Cancer Therapy Reviews, Vol. 7, Iss. 4, 2011-11 ,pp. : 282-289

Bentham Science Publishers

Access to resources Recommend Favorite

Expression of E-cadherin and KRAS mutation may serve as biomarkers of cetuximab-based therapy in metastatic colorectal cancer

By                  

Oncology Letters, Vol. 5, Iss. 4, 2013-01 ,pp. : 1295-1300

Spandidos Publications

Access to resources Recommend Favorite

Analysis of PTEN, BRAF and PI3K status for determination of benefit from cetuximab therapy in metastatic colorectal cancer patients refractory to chemotherapy with wild-type KRAS

By Tural Deniz   Batur Sebnem   Erdamar Sibel   Akar Emre   Kepil Nuray   Mandel Nil   Serdengeçti Süheyla  

Tumor Biology, Vol. 35, Iss. 2, 2014-02 ,pp. : 1041-1049

Springer Publishing Company

Access to resources Recommend Favorite